Appointment of Marylyn D. Ritchie, PhD, FACMI, as the inaugural Vice Dean of Artificial Intelligence and Computing for the Perelman School of Medicine. Read more.

Abstract figure

Using electronic health record data from a national collaboration of pediatric health systems, this study examined the effectiveness of BNT162b2 vaccines for preventing COVID-19 infections and severe disease among previously uninfected children and adolescents.

Authors

Qiong Wu, PhD*; Jiayi Tong, MS*; Bingyu Zhang, MS; Dazheng Zhang, MS; Jiajie Chen, PhD; Yuqing Lei, MS; Yiwen Lu, BS; Yudong Wang, PhD; Lu Li, BA; Yishan Shen, MS; Jie Xu, PhD; L. Charles Bailey, MD, PhD; Jiang Bian, PhD; Dimitri A. Christakis, MD, MPH; Megan L. Fitzgerald, PhD; Kathryn Hirabayashi, MPH; Ravi Jhaveri, MD; Alka Khaitan, MD; Tianchen Lyu, MS; Suchitra Rao, MBBS, MSCS; Hanieh Razzaghi, PhD, MPH; Hayden T. Schwenk, MD, MPH; Fei Wang, PhD; Margot I. Gage Witvliet, PhD; Eric J. Tchetgen Tchetgen, PhD; Jeffrey S. Morris, PhD; Christopher B. Forrest, MD, PhD; and Yong Chen, PhD.

Angela DeMichele, MD and her team have recently received a $10 million grant to expand their work on how to prevent breast cancer recurrence, which is often fatal.

Caption
Apply for CCEB Membership! (click to learn more)
Weight
-18
Active
On
Mohsin Shah MBBS, MSCE

Mohsin Shah, MBBS, MSCE

Mohsin Shah is the Associate Director of Global Integrated Evidence - Epidemiology & RWE Oncology at Boehringer Ingelheim, where he collaborates cross-functionally to assist in the development of strategies and real-world studies to enhance clinical development, add to regulatory submissions, inform payer interactions, and respond to changes in the marketplace, and enhance internal decision making. Dr. Shah is a clinical pharmacoepidemiologist by training with over eight years of experience conceptualizing, designing, and leading real-world studies. He has published over 26 peer-reviewed articles and presented over 20 conference presentations. Dr. Shah completed a T-32-funded postdoctoral fellowship in applied pharmacoepidemiology and graduated with a Master of Science in Clinical Epidemiology (MSCE) degree from the Perelman School of Medicine, University of Pennsylvania. Before this training, he completed a postdoctoral fellowship in internal medicine and oncologic emergency medicine at the UT MD Anderson Cancer Center. He received his medical doctorate from the University of Health Sciences. Dr. Shah’s expertise lies in (a) evaluating novel interventions using real-world data and state-of-the-art biostatistical and missing data methods (b) generating real-world evidence from such novel interventions, and (c) optimizing pharmacoepidemiology research methods to adapt to patients with cancer.

Alternate email: mohsin.shah@boehringer-ingelheim.com

 

Dovie L. Watson, MD, MSCE

Dovie L. Watson, MD, MSCE

Dr. Watson is an infectious diseases physician-scientist whose clinical HIV research program focuses on accelerating equitable HIV pre-exposure prophylaxis (PrEP) service delivery and eliminating stigma and discrimination in sexual health, with particular attention to Black LGBTQ+ adults in the United States. She has particular expertise in clinical ID epidemiology, health equity, HIV prevention research, LGBTQ+ Health, and community-engaged research. Dr. Watson’s work has led to several publications delineating provider-level, structural, and systemic barriers and facilitators to equitable PrEP equity for patients with multiple marginalized identities. She is the recipient of institutional and federal grants from the National Institutes of Health, including a Career Development Award (K23) from the National Institute of Mental Health, which an equity-focused implementation science grant to design and pilot a novel multifaceted implementation strategy to address provider behaviors and organization-level practices that affect PrEP equity for Black patients in Philadelphia. Dr. Watson’s long-term goal is to eliminate behavioral and structural barriers to PrEP implementation within clinical and community settings in order to achieve PrEP equity among Black and LGBTQ+ populations.

Dr. Watson received her B.A. degree from Cornell University and her medical degree from the Northwestern University. She completed her internship and residency at the University of Chicago, during which time she also completed a Medical Ethics fellowship at the University of Chicago MacLean Center for Clinical Medical Ethics. She subsequently completed her Infectious Diseases (ID) fellowship and obtained her Master of Science in Clinical Epidemiology (MSCE) degree from the University of Pennsylvania.

“That’s why expert opinion ends up being very important here,” said Expert Panel Co-Chair Angela DeMichele, MD, MSCE, FASCO, of Penn Medicine. “We don’t have data on optimal sequencing in the first, second, and third line, and we don’t have data on head-to-head comparison for drugs that are targeting PIK3CA pathway alterations. That’s where an expert guideline comes in—when you don’t have that kind of feedback.”

Monday, September 16, 2024 - Tuesday, September 17, 2024
12:00 am - 11:59 pm

Data shows that cases of inflammatory bowel disease and colon cancer are on the rise. At the same time, social media is inundated with ads and influencers touting products that promise to boost what’s broadly called “gut health.” How do we separate the facts from the fads? Dr. Shazia Siddique, an assistant professor of gastroenterology at the University of Pennsylvania, joins John Yang to discuss.

 

Subscribe to